- Home
- KG vs SGHT Comparison
KG vs SGHT Comparison
Compare KG & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KG
- SGHT
- Stock Information
- Founded
- KG N/A
- SGHT 2011
- Country
- KG Bermuda
- SGHT United States
- Employees
- KG N/A
- SGHT N/A
- Industry
- KG Property-Casualty Insurers
- SGHT Medical Specialities
- Sector
- KG Finance
- SGHT Health Care
- Exchange
- KG Nasdaq
- SGHT Nasdaq
- Market Cap
- KG 225.0M
- SGHT 193.2M
- IPO Year
- KG N/A
- SGHT 2021
- Fundamental
- Price
- KG $24.89
- SGHT $5.17
- Analyst Decision
- KG
- SGHT Buy
- Analyst Count
- KG 0
- SGHT 8
- Target Price
- KG N/A
- SGHT $4.50
- AVG Volume (30 Days)
- KG 14.1K
- SGHT 226.8K
- Earning Date
- KG 11-15-2025
- SGHT 11-06-2025
- Dividend Yield
- KG N/A
- SGHT N/A
- EPS Growth
- KG N/A
- SGHT N/A
- EPS
- KG 9.13
- SGHT N/A
- Revenue
- KG $9,983,137.00
- SGHT $76,303,000.00
- Revenue This Year
- KG N/A
- SGHT N/A
- Revenue Next Year
- KG N/A
- SGHT $12.04
- P/E Ratio
- KG $2.85
- SGHT N/A
- Revenue Growth
- KG 250.18
- SGHT N/A
- 52 Week Low
- KG $20.51
- SGHT $2.03
- 52 Week High
- KG $36.80
- SGHT $5.48
- Technical
- Relative Strength Index (RSI)
- KG 39.22
- SGHT 74.58
- Support Level
- KG $24.92
- SGHT $3.22
- Resistance Level
- KG $26.44
- SGHT $5.31
- Average True Range (ATR)
- KG 0.69
- SGHT 0.32
- MACD
- KG 0.04
- SGHT 0.17
- Stochastic Oscillator
- KG 25.12
- SGHT 92.99
About KG Kestrel Group Ltd.
Kestrel Group Ltd is specializes in providing fronting services to insurance program managers, MGAs, reinsurers, and reinsurance brokers. The Group facilitates insurance transactions utilizing its management contracts with four insurance carriers. Its line business includes casualty, workers' compensation, catastrophe-exposed property, and non-catastrophe-exposed property, with diverse risk durations, sizes, and product types.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.